Datos Health Ltd.

Datos Health Ltd. specializes in AI-driven remote patient monitoring, enhancing patient care through customizable healthcare solutions and innovative clinical pathways. Founded in 2015, Datos Health Ltd. is based in New York, US, and specializes in remote patient monitoring solutions.

The company was founded by Haim Harel and Uri Bettesh, who both have a history of leadership in technology and healthcare. In April 2020, Datos Health raised USD 7 mn in Series A funding, led by Crescendo Venture Partners, with participation from Angular Ventures, Industry Ventures, and Vertex Ventures Israel. The company has completed 3 deals to date, with the most recent deal occurring in April 2020. Datos Health offers an AI-driven remote patient monitoring platform, OpenCare, which enhances hybrid care pathways through customizable solutions.

OpenCare enables healthcare providers to create, adapt, and optimize clinical programs, featuring over 300 predefined clinical pathways for various needs, including cardiac rehabilitation and chronic disease management. The platform emphasizes automated workflows and supported self-care, serving a diverse clientele across North America, Europe, and Australia with device-agnostic solutions. Datos Health operates on a subscription-based revenue model, engaging clients through partnerships for its remote patient monitoring services. Healthcare organizations subscribe to the OpenCare platform, gaining access to tailored CareApps and automated workflows designed to improve patient care.

The pricing structure is based on the level of service and specific clinical pathways utilized, with offerings such as the ReadyCare programs targeting specific patient populations while maintaining flexibility for various clinical workflows. Datos Health plans to leverage its recent Series A funding of USD 7 mn to expand its product offerings and market reach. The funding will support the ongoing development of new features within the OpenCare platform. Additionally, the company aims to target expansion into new geographic markets, particularly in Europe and Australia, by 2022, enhancing its global footprint in the healthcare technology sector.